Investor Relations Home

About Natera

About Natera

Natera is a rapidly-growing diagnostics company with proprietary bioinformatics and molecular technology for analyzing DNA. Natera’s complex technology has been proven clinically and commercially in the prenatal testing space and the Company is actively researching its applications in the liquid biopsy space for developing products with oncology applications.

Since 2009, Natera has launched seven molecular diagnostic tests, many of which are available through major health plans accounting for more than 140 million covered lives in the United States. The Company’s own robust laboratory processes thousands of genetic tests per month.

Natera’s goal is to transform the way people – both providers and patients – respond to and manage genetic diseases.

Learn More About Natera

Stock Information

NTRA (Common Stock)
ExchangeNASDAQ CM (US Dollar)
Price$9.89
Change (%) Stock is Down 0.03 (0.30%)
Volume96,763
Data as of 11/22/17 4:00 p.m. ET
Minimum 15 minute delay
Refresh quote
Stock chart for: NTRA.O.  Currently trading at $9.89 with a 52 week high of $14.76 and a 52 week low of $7.35.

Recent News

Natera Reports Third Quarter 2017 Financial Results - 11/08/17
SAN CARLOS, Calif., Nov. 8, 2017 /PRNewswire/ -- Natera, Inc. (NASDAQ:  NTRA), a leader in non-invasive genetic testing and the analysis of circulating cell-free DNA, today reported financial results for the third quarter ended September 30, 2017 and... More»
Natera Selected for Circulating Tumor DNA Study in Colorectal Cancer - 11/06/17
Second Study with Denmark's Aarhus University to Leverage Signatera™ (RUO) Personalized ctDNA Technology SAN CARLOS, Calif., Nov. 6, 2017 /PRNewswire/ -- Natera, Inc., (NASDAQ: NTRA), a global leader in cell-free DNA testing, today announced a s... More»
Natera Inc. Announces Third Quarter 2017 Earnings Conference Call - 11/02/17
SAN CARLOS, Calif., Nov. 2, 2017 /PRNewswire/ -- Natera (NASDAQ: NTRA), a leader in non-invasive genetic testing, today announced that it will release results for its third quarter ended September 30, 2017 after the market close on November 8, 2017. ... More»
Natera Chosen for Longitudinal Circulating Tumor DNA Study in Breast Cancer - 11/01/17
Collaboration with Imperial College London and University of Leicester to Leverage Signatera™ (RUO) Personalized ctDNA Technology SAN CARLOS, Calif., Nov. 1, 2017 /PRNewswire/ -- Natera, Inc., (NASDAQ: NTRA), a global leader in cell-free DNA tes... More»
Natera's Panorama Non-Invasive Prenatal Test Now Available for Screening Twin Pregnancies - 10/02/17
First NIPT to Determine Zygosity for Twins as Early as Nine Weeks' Gestation SAN CARLOS, Calif., Oct. 2, 2017 /PRNewswire/ -- Natera (NASDAQ: NTRA), a leader in non-invasive genetic testing and the analysis of circulating cell-free DNA, today an... More»

Upcoming Events

There are currently no events scheduled.

The information provided in this area of the website is maintained by a third-party service. Natera is not responsible for the accuracy, currency or completeness of the information contained herein.
Data provided by Nasdaq. Minimum 15 minutes delayed.